

UCSF

UC San Francisco Previously Published Works

Title

Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.

Permalink

<https://escholarship.org/uc/item/5mq003j9>

Journal

The AAPS journal, 23(5)

ISSN

1550-7416

Authors

Bajaj, Ruchika
Chong, Lisa B
Zou, Ling
et al.

Publication Date

2021-09-01

DOI

10.1208/s12248-021-00631-8

Peer reviewed



Published in final edited form as:

AAPS J. ; 23(5): 106. doi:10.1208/s12248-021-00631-8.

Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein

Ruchika Bajaj¹, Lisa B Chong¹, Ling Zou¹, Eleftheria Tsakalozou², Zhanglin Ni², Kathleen M Giacomini¹, Deanna L Kroetz¹

¹Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA

²Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD USA

Abstract

P-glycoprotein (P-gp) plays a critical role in drug oral bioavailability and modulation of this transporter can alter the safety and/or efficacy profile of substrate drugs. Individual oral molecular excipients that inhibit P-gp function have been considered as a mechanism for improving drug absorption, but a systematic evaluation of the interaction of excipients with P-gp is critical for informed selection of optimal formulations of proprietary and generic drug products. A library of 123 oral molecular excipients was screened for their ability to inhibit P-gp in two orthogonal cell-based assays. β -Cyclodextrin and Light green SF yellowish were identified as modest inhibitors of P-gp with IC₅₀ values of 168 μ M (95% CI, 118–251 μ M) and 204 μ M (95% CI, 5.9–1745 μ M), respectively. The lack of effect of most of the tested excipients on P-gp transport provides a wide selection of excipients for inclusion in oral formulations with minimal risk of influencing the oral bioavailability of P-gp substrates.

Keywords

P-glycoprotein; oral excipients; Calcein-AM assay; digoxin flux; screening assays

Corresponding Author: Deanna L. Kroetz, Ph.D., Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, 1550 4th Street RH584E, San Francisco, CA 94143-2911, (415) 476-1159, deanna.kroetz@ucsf.edu.

Author Contributions

Conceptualization: Ling Zou, Eleftheria Tsakalozou, Zhanglin Ni, Kathleen M. Giacomini and Deanna L. Kroetz

Investigation: Ruchika Bajaj, Lisa B. Chong and Ling Zou

Formal analysis: Ruchika Bajaj, Lisa B. Chong and Ling Zou

Supervision: Kathleen M. Giacomini and Deanna L. Kroetz

Writing – original draft: Ruchika Bajaj and Deanna L. Kroetz

Writing – review & editing: Ruchika Bajaj, Lisa B. Chong, Ling Zou, Eleftheria Tsakalozou, Zhanglin Ni, Kathleen M. Giacomini and Deanna L. Kroetz

Conflict of Interest Statement

The authors have no relevant financial or non-financial interests to disclose.

Introduction

P-glycoprotein (P-gp, also known as Multidrug Resistance Protein 1 (MDR1) or ATP-binding cassette transporter B1 (ABCB1)) is an ABC transporter with established roles in drug disposition, efficacy and drug-drug interactions (DDIs) [1, 2]. Its ability to transport numerous structurally diverse compounds, including xenobiotics and endogenous substrates, and its ubiquitous expression in humans in tissues such as the intestine, kidney, liver, and brain underlie its critical role in pharmacology [3–5]. P-gp is well recognized for its ability to cause multidrug resistance in cancer through efflux of drugs out of the tumor [6]. In addition, P-gp plays an important role in intestinal absorption and hepatic and urinary excretion of drugs and serves as a biochemical barrier to the entry of xenobiotics into the central nervous system, the placenta and the testis [1, 7]. The contribution of P-gp to the pharmacokinetics and pharmacodynamics of many drug substrates has led to significant interest in understanding the regulation of P-gp function by drugs and other xenobiotics [2, 3].

Oral formulations are the most common, convenient and preferred route for drug administration and may involve drug release at the specific target site of absorption in a controlled manner [8, 9]. To improve the absorption of a drug molecule with suboptimal physiochemical properties (*e.g.*, low solubility, limited permeability or high metabolism), molecular excipients are included in the oral dosage form [10, 11]. Excipients are substances other than the active pharmaceutical ingredient that are added to the formulation to increase stability, solubility, swellability, viscosity, biodegradability or buffering capacity. In addition, excipients can add nutrients, flavor or color, increase absorption, bioavailability or shelf life of the active ingredient, and add pH dependency or oxidation-reduction potential for its mechanistic action at a specific site [10, 12, 13]. Different excipients play distinct roles in oral dosage forms and significantly influence characteristics of the final product [14–16].

Oral molecular excipients are considered safe additives to drugs with the potential to interact with cellular proteins and alter their function. A recent study using computational predictions, cell-based assays and *in vivo* rodent studies identified excipients that interact with numerous target proteins and clinical safety targets [17]. One concern is that interactions between P-gp and excipients may lead to variability in absorption between drug formulations. Previous studies have largely focused on the identification of excipients that inhibit P-gp to increase drug bioavailability. The most widely studied excipients identified as P-gp inhibitors are polyethylene glycols, polysorbates, Cremophor EL and pluronics [18–27]. The inhibitory interaction of Vitamin E-PEG with P-gp has been exploited to increase the oral absorption of paclitaxel [28]. Similarly, the absorption of ganciclovir has been enhanced using excipients such as Cremophor EL-35, Pluronic block copolymer F68, PEG-400, Tween-80 and Labrasol, and the bioavailability of ranitidine was significantly increased with PEG-400 [29–31].

Still, many excipients have not been screened for interactions with P-gp. In the current study, 123 orally administered molecular excipients listed in the FDA Inactive Ingredient Database (<https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm>) [32] were screened using two

orthogonal systems, HEK and MDCK cells overexpressing human P-gp. These findings expand our understanding of the interaction of oral molecular excipients with P-gp.

Materials and Methods

Materials

Calcein-AM (ENZ-52002) was purchased from Enzo Life Sciences. Poly D-lysine (P6407), cyclosporine A (C1832), elacridar (SML0486), digoxin (D6003) and hygromycin B (10843555001) were all purchased from Sigma Aldrich. Verapamil (06-541-G) was purchased from Fisher Scientific. Dulbecco's Modified Eagle Medium with Glucose (DME-H21, CCFAA005), fetal bovine serum (FBS, CCFAP004), penicillin-streptomycin (CCFGK004), trypsin-EDTA (CCFGP001) and phosphate-buffered saline (PBS, CCFAL001) were all purchased from the UCSF Cell Culture Facility. Dulbecco's PBS (DPBS) without calcium chloride and magnesium chloride was from Gibco (14190) and ³H-labeled digoxin (NET222250UC) was purchased from Perkin Elmer. Purchasing information for excipients was reported previously [33].

Cell lines and culture

Flp-InTM-293 human embryonic kidney cells transfected with pcDNA5/FRT plasmid with (HEK293-MDR1) or without (HEK293-EV) the ABCB1 cDNA were described previously [34]. Cells were cultured in T-25 flasks in DMEM medium with 10% FBS, penicillin (100 U/ml), streptomycin (100 µg/ml) and hygromycin B (75 µg/ml) at 37°C in a humidified incubator with 5% CO₂. MDCK-hMDR1-cMDR1-KO cells have endogenous canine MDR1 knocked out and stably express human MDR1 and were kindly provided by Dr. Per Artursson (Uppsala University) along with the corresponding MDCK-cMDR1-KO cells [35, 36]. MDCK-hMDR1-cMDR1-KO cells were grown in similar conditions as the HEK cells except that hygromycin B was added at 400 µg/ml. Cells were passaged every 3–4 days after reaching 80–90% confluency by incubating with 1 ml of 0.25% Trypsin-EDTA at 37°C without shaking for 5–10 min, resuspending in DMEM medium and transferring to a 15 ml Falcon tube. The cell suspension was centrifuged at 100g for 5 min, and the resulting cell pellet was resuspended in 4–5 ml of supplemented DMEM medium as described above, then diluted at a 1:4 or 1:5 ratio in a final volume of 8 ml and placed into a T-25 flask. Cells were not used beyond passage 10.

Calcein accumulation assay

A calcein accumulation assay was performed as described previously [37]. In brief, HEK-MDR1 and HEK-EV cells were seeded onto 96-well plates coated with 50 µg/ml poly-D-lysine at a density of 8×10^5 cells/0.32 cm², 24 hours prior to experiments. Cells were washed thrice with ice-cold PBS and incubated with calcein-AM (5 µM) in the presence and absence of the studied excipient or the known P-gp inhibitor verapamil (500 µM) at 37°C for 1 hr. The calcein accumulation assays were terminated by washing cells thrice with ice-cold PBS. The amount of accumulated calcein was quantified by measuring intracellular fluorescence at an excitation/emission of 485 nm/590 nm using a Genios Pro fluorescence plate reader (Tecan, Switzerland). The inhibitory effect of tested excipients

on P-gp-mediated specific transport of calcein-AM was expressed as a normalized calcein accumulation ratio using the following equation:

$$\text{Normalized Calcein Accumulation Ratio} = \frac{P - gp + I / P - gp - I}{EV + I / EV - I}$$

where (P-gp + I) and (P-gp – I) represent the fluorescence of accumulated calcein in HEK293-MDR1 cells in the presence and absence of the excipient or known inhibitor, respectively and (EV + I) and (EV – I) represent the fluorescence of accumulated calcein in the HEK293-EV cells in the presence and absence of the excipient or known inhibitor, respectively.

Digoxin flux assay

For transwell assays, procedures were modified from published reports [36, 38]. Briefly, 2.1×10^4 MDCK-hMDR1-cMDR1-KO cells/well were seeded onto Falcon 24 multiwell inserts with a microporous polyethylene terephthalate membrane (351181, Corning Life Sciences) and complementary 24 well plate (353047, Corning Life Sciences). During differentiation, the volume of medium was 300 μ l in the apical chamber and 1000 μ l in the basal chamber. The cells were differentiated for 7–10 days and lucifer yellow permeability assays were carried out to check the integrity of the cell monolayer before the digoxin flux assays. Cells were washed twice with Hanks' balanced salt solution (HBSS) at pH 7.4 with calcium chloride and magnesium chloride (Gibco 14025). Lucifer yellow (0.1 mg/ml) in HBSS was added to the apical chamber and the basal chamber was filled with fresh HBSS. The assembled plate was kept at 37°C for 1 hour and 15 μ l aliquots were taken from the basal chamber for fluorescence measurements. The % permeability was calculated on a per-well basis as

$$\frac{(F_w - F_b) \times 100}{(F_{ly} - F_b)}$$

where F_w is the fluorescence of a sample from an individual well, F_b is the fluorescence of HBSS and F_{ly} is the fluorescence of the lucifer yellow solution. Wells with cell monolayer permeability of >3% were not used for the digoxin flux assay. After lucifer yellow measurements, cells were washed with HBSS before the addition of fresh medium to the apical and basal chambers. The cells recovered overnight and were used the next day for digoxin flux assays.

Digoxin flux from the basal to apical side was measured as described in previous studies [38]. Cells were washed twice with HBSS before addition to the basal chamber (700 μ l) of an HBSS solution of digoxin (6.35 nM 3 H-labeled, final concentration 2.5 μ M) in the presence or absence of the known P-gp inhibitor cyclosporine A (10 μ M) or the indicated concentration of studied excipient. The same concentration of known inhibitor or excipient and 0.1 mg/ml lucifer yellow were added to the apical chamber in HBSS (225 μ l). Plates were incubated at 37°C with shaking at 300 rpm and 25 μ l aliquots were removed from the apical compartment at 1, 1.5 and 2 hours and replaced with the same volume of apical

solution. Samples (25 μ l) were also taken from the basal chambers before the start and at the end of each experiment to calculate the dpm/pmole ratio and for mass balance calculations. Scintillation fluid (2.5 ml, 6013141, Perkin Elmer) was added to all apical and basal samples and radioactivity was measured by liquid scintillation counting (Beckman LS6500). Additionally, 15 μ l samples were collected from the basal chamber at the end of the assay for lucifer yellow fluorescence measurements. For data analysis, digoxin dpm counts from the apical samples were converted to pmoles using the measured radioactivity in the substrate solution. The rate of basal to apical transport was calculated by linear regression using the timed samples and the effect of each excipient was expressed as a fold change in transport rate compared to digoxin alone. Fold change in rate was calculated as

$$\text{Fold change} = \frac{R_{(B-A)+I}}{R_{(B-A)-I}}$$

where $R_{(B-A)+I}$ and $R_{(B-A)-I}$ are the rates of digoxin transport from the basal to apical side in the presence and absence of known inhibitor or excipient, respectively. The permeability of the cell monolayer at the end of the digoxin flux assay was calculated using lucifer yellow as described above.

Excipient screening

An initial pool of 123 excipients for screening was a subset of 136 FDA-approved excipients that have been described previously [33]. Excipients which are no longer used, commercially unavailable, poorly soluble or formulated for inhalation were not included in the screening. The excipients were screened at a concentration of 200 μ M except those with limited solubility (10 μ M for Yellow 62 and 50 μ M for docusate sodium salt, sodium lauryl sulfate, cetyl pyridinium chloride, D&C Red No. 6, Oil Orange SS, propylparaben, glyceryl caprylate and Yellow AB) and sugars (1 mM for sucrose, dextrose, D-tagatose, mannose, galactose, maltose, fructose and sucralose). The screening of excipients included three technical replicates for the calcein accumulation assays and two technical replicates for the digoxin flux assays.

Dose-response analysis

Potential P-gp inhibitors identified in each respective screen were further evaluated over a range of excipient concentrations using the same assays. IC_{50} estimates were obtained by fitting the dose-response data using the log (inhibitor) vs. response – variable slope (four parameters) relationship in GraphPad Prism 9.

Results

Screening overview

A total of 123 molecular excipients were screened for their ability to inhibit P-gp transport function in two different assays, a calcein-AM fluorescence-based accumulation assay and a digoxin flux assay. The screened excipients represent diverse functional classes and include flavoring agents (25%), dyes (20%), antimicrobial agents (12%), buffering agents (8%), nutrient supplements (6%), solubilizing agents (4%), surfactants (4%), antioxidants

(3%), diluents (3%), coating agents (2%) and plasticizing agents (2%). The overview of the screening process is outlined in Figure 1. Potential P-gp inhibitors were subsequently examined in dose-response studies to estimate IC₅₀ values. Finally, the potency of excipients confirmed as inhibitors from either assay was compared to estimated intestinal concentrations of the tested excipients to evaluate the potential for inhibition of human P-gp *in vivo*.

Inhibition of calcein accumulation by excipients

Calcein accumulation was ~3-fold higher in the HEK-EV cells compared to the HEK-MDR1 cells and was robustly inhibited in the HEK-MDR1 cells by the known P-gp inhibitor verapamil (Figure 2A). There was minimal effect of verapamil on calcein accumulation in the HEK-EV cells (Figure 2A) and the normalized calcein accumulation ratio was 2.2 for verapamil (Figure 2B). Verapamil was included as a positive control in all screening assays. The distribution of normalized calcein accumulation ratios is shown in Figure 2C and the accumulation ratios are tabulated for all tested excipients in Table I. A threshold of 40% increase in normalized accumulation ratios was used to identify the excipients with the most potent effects on P-gp activity and identified 10 potential inhibitors. Individual inspection of the +excipient/-excipient calcein ratios in each cell line for these potential inhibitors differentiated between specific effects on P-gp activity from non-specific effects, possibly due to cytotoxicity. Only two excipients (D&C Red No. 6 and D&C Brown No. 1) inhibited calcein flux at least 40% in the MDR1-overexpressing cells and had no effect in the EV cells (Figure 2D). Seven excipients were eliminated as potential inhibitors due to a non-specific effect resulting in a decrease in calcein ratios (+excipient/-excipient) in both the control and MDR1-overexpressing cells (lower left quadrant in Figure 2D) that translated into increased normalized calcein accumulation ratios (benzalkonium chloride, docusate sodium, D&C Red No. 33, D&C Red No. 27, D&C Red No. 28, D&C Orange No. 4 and D&C Red No. 3). The remaining excipient with a normalized accumulation ratio >1.4 (NaHCO₃) was also eliminated since it demonstrated <40% increase in calcein accumulation in the MDR1-overexpressing cells. Dose-response studies with the two putative inhibitors failed to validate either of these dyes as an inhibitor of P-gp at concentrations <300 μM (Supplemental Figure 1), which is more than 100-fold higher than the maximum predicted intestinal concentration based on the maximum potency per unit dose listed in the FDA Inactive Ingredient Database [32].

Inhibition of digoxin flux by excipients

Basal to apical flux of digoxin was ~10-fold higher in the MDCK cells expressing human MDR1 compared to the control cells that do not express canine or human MDR1. Cyclosporine, a known inhibitor of P-gp, reduced digoxin flux in the human MDR1-overexpressing cells to similar levels as in the control cells, indicating specific transport of digoxin by P-gp (Figure 3A). Excipients were screened to identify potential inhibitors of digoxin flux, using a decrease in flux of at least 40% as the cutoff (Figure 3B and Table I). Four excipients were identified as potential inhibitors, two of which were not considered further because of their interference with fluorescence measurements of lucifer yellow (D&C Red No. 28) or increased lucifer yellow permeability (rhodamine B) (Figure 3C). The remaining two potential inhibitors were light green SF yellowish (45% decrease)

and β -cyclodextrin (β -CD, 75% decrease). Dose-response analyses confirmed both of these excipients as modest inhibitors of digoxin flux, with IC_{50} estimates of 168 μ M (95% CI, 118–251 μ M, Figure 3D) and 204 μ M (95% CI, 5.9–1745 μ M, Figure 3E) for β -CD and light green SF yellowish, respectively (Figures 3D and 3E). In addition to D&C Red No. 28 and rhodamine B, seven more excipients could not be evaluated as P-gp inhibitors in this assay due to their effects on cell monolayer permeability (benzalkonium chloride, docusate sodium salt, sodium lauryl sulfate, cinnamaldehyde and cetyl pyridinium chloride) or interference with the lucifer yellow assay (D&C Red No. 27, D&C Red No. 3) (Figure 3C and Table I).

Discussion

Intestinal P-gp plays a critical role in limiting the bioavailability of numerous drugs and its inhibition or induction can result in clinically significant drug-drug interactions [2–4]. While drug-drug interactions involving P-gp are extensively characterized both during drug development and post marketing, P-gp interactions with excipients have largely been limited to a few functional classes [18, 21, 39–41]. Molecular excipients are commonly used to optimize oral drug formulations and are generally considered to be inert. This tenet of excipient inertness was tested in the current study with a panel of 123 oral molecular excipients evaluated for their ability to modulate P-gp function *in vitro* using two orthogonal methods, an accumulation assay and a flux assay that indirectly and directly measured P-gp transport, respectively. The tested oral excipients are used as flavoring agents, solubilizing agents, antimicrobials, buffering agents, dyes and as nutrient supplements; most were inert with respect to P-gp transport activity. Light green SF yellowish, a dye, and β -CD, a solubilizing agent, were confirmed inhibitors with modest potency that is not predicted to influence P-gp function in the human intestine. These findings provide useful information towards developing an excipient selection strategy for pharmacologically active ingredients in oral dosage forms.

Excipients can be added at high amounts relative to the active pharmaceutical ingredient and in some cases are predicted to reach high intestinal concentrations within the limited volume (~250 ml) of the small intestine [32]. The use of high screening concentrations in both assays was based on an interest in only the most potent inhibitors with likely clinical relevance and the expectation of relatively high gut concentrations of the screened excipients. Despite these high concentrations, very few excipients had any effect on P-gp-mediated transport of either calcein-AM or the cardiac glycoside digoxin. Only two excipients with a normalized calcein accumulation ratio >1.4, D&C Red No. 6 and D&C Brown No. 1, increased intracellular levels of calcein fluorescence 40% or greater in HEK cells overexpressing human MDR1, without an effect on the control cells. However, dose-response analyses did not confirm significant inhibition of P-gp-mediated transport using the calcein accumulation assay and neither of these dyes reached the inhibition threshold for basal to apical flux of digoxin. It is worth noting that D&C Brown No. 1 inhibited basal to apical flux of digoxin by 32% and may warrant further evaluation as a potential P-gp inhibitor. The two excipients identified as possible P-gp inhibitors in the digoxin flux assay, light green SF yellowish and β -CD, were weak inhibitors with IC_{50} values of 204 μ M and 168 μ M, respectively. Light green SF yellowish increased calcein accumulation 85%

and 44% in the HEK-MDR1 and HEK-EV cells, respectively, resulting in a normalized accumulation ratio (1.28) slightly below the cutoff for inhibitor classification. Considering that the increase in calcein fluorescence with addition of light green SF yellowish in the MDR1-overexpressing cells was two-fold higher than in control cells, the results from this screen also support its classification as a P-gp inhibitor. In contrast, β -CD had no effect on calcein-AM efflux.

Most of the excipients screened in the present study have not been previously evaluated for their potential to inhibit P-gp. One exception is the solubilizing agent β -CD, a cyclic oligosaccharide consisting of (α -1,4)-linked α -D-glucopyranose units forming cages with hydrophobic cavities and hydrophilic outer surfaces [42]. β -CD has been reported to enhance the intestinal absorption of berberine hydrochloride, a P-gp substrate, not only by increasing its dissolution rate, but also by inhibiting substrate-stimulated P-gp ATPase activity [43]. Related cyclodextrin derivatives have been extensively studied as P-gp inhibitors. Dimethyl- and methyl- β -CD have been characterized as P-gp inhibitors in cellular efflux assays and *in situ* intestinal absorption studies [40, 41, 44–49]. One mechanism for this inhibition is release of P-gp from the cell membrane [44, 45, 47, 49]. Dimethyl- β -CD was also shown to improve the bioavailability of tacrolimus in rats [48], supporting the potential for cyclodextrins to inhibit P-gp and enhance bioavailability in humans. In contrast, hydroxypropyl- β -CD, an excipient in the oral solution of itraconazole commonly used in DDI studies, was recently demonstrated to reduce the permeability of fenebrutinib across an MDCK monolayer and to limit fenebrutinib absorption in dogs [50]. These findings suggest complicated interactions between drugs and cyclodextrins in humans, including the potential for unintended DDIs during studies undertaken to inform drug labeling.

A recent screen of the same excipient library against breast cancer resistance protein (BCRP) indicated little overlap between inhibition of BCRP and P-gp. Only light green SF yellowish was identified in both studies, with a much higher potency for inhibition of BCRP in membrane vesicles ($IC_{50} = 1.0 \mu M$) compared to inhibition of P-gp-mediated digoxin flux in the current study [51]. For drugs that are substrates of both P-gp and BCRP, the combined inhibition of these transporters by light green SF yellowish could enhance bioavailability through independent effects on the transporters. These findings may warrant caution for oral drug formulations containing light green SF yellowish.

Although the MDCK transwell flux assay is considered a reasonable model for P-gp-mediated efflux, the lack of host and microbial metabolizing enzymes, the inability to mimic the transit of drugs through the intestine, and artificially high levels of P-gp expression limit the direct extrapolation of these findings to humans. The maximum amount per unit dose of β -CD and light green SF yellowish in marketed drug formulations is 133 mg and 40 mg, respectively [32]. Considering an intestinal volume of 250 ml, this translates into a predicted maximum intestinal concentration (I_{max}) of 470 μM for β -CD and 214 μM for light green SF yellowish. The FDA regulatory guidance *In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions* classifies transporter inhibitors of potential clinical significance if the $[I_{max}]$ to $[IC_{50}]$ ratio is >10 [52]. $[I_{max}]/[IC_{50}]$ values of 1.1 and 2.8 for light green SF yellowish and β -CD, respectively, suggest that neither of these *in vitro* P-gp inhibitors is likely to show clinically significant inhibition of P-gp in

humans (Supplemental Table I). However, the incorporation of increased amounts of β -CD into new formulations should be carefully evaluated for potential P-gp interactions.

A normalized calcein accumulation ratio was utilized to identify specific effects on P-gp transport, as applied in earlier studies of P-gp inhibition to reverse drug sensitivity [53]. However, this ratio led to numerous false positives and negatives. It was expected that there would be no effect on calcein-AM efflux in the HEK-EV cells, which held true for both D&C Red No. 6 and D&C Brown No. 1. However, closer inspection of the other potential inhibitors based on the normalized calcein accumulation ratio identified a number of excipients that reduced fluorescence to a larger extent in HEK-EV cells than in HEK-MDR1 cells, such that the normalized ratio was >1.4 , the cutoff for inhibition. These false positives could be due to toxicity of the compounds, which was consistent with permeability measurements of lucifer yellow across the MDCK cell monolayer for benzalkonium chloride and docusate sodium. Additionally, since calcein-AM is also a substrate for other ABC transporters endogenously expressed in HEK293 cells [54–56], activating effects of these excipients on one or more of these transporters could lead to increased calcein-AM efflux and a corresponding decrease in fluorescence. Interestingly, a number of the excipients identified as false positives in the calcein accumulation assay (D&C Red No. 3, D&C Red No. 27, D&C Red No. 28, D&C Orange No. 4, D&C Red No. 33 and docusate sodium) led to confounding results in a similar screen against BCRP [51]. These excipients inhibited BCRP overexpressed in Sf9 membrane vesicles, but not in HEK293 cells overexpressing BCRP. While these BCRP results may be explained at least in part by differences in availability of the excipient in the Sf9 inside-out vesicles compared to HEK293 cells, this cannot explain the current results with P-gp since both assays used in this study required the excipients to be membrane permeable for transporter inhibition. In addition to false positives, the normalized accumulation ratio also leads to potential false negatives. For example, acid blue 9, naphthol blue black, and butylparaben did not reach the inhibitor criteria based on the normalized accumulation ratio, although each increased calcein fluorescence in the MDR1-overexpressing cells by at least 60%. Although these excipients had no effect on digoxin flux, further investigation is warranted for potential interactions with P-gp.

Differences in results with the two screening assays have several plausible explanations. First, two substrates were used which may have different mechanisms of transport via P-gp. While both calcein-AM and digoxin are highly hydrophobic, structural differences may result in interactions with distinct residues in P-gp during transport. Similarly, identified excipient inhibitors may interact with different residues in P-gp, making it reasonable that the detection of P-gp inhibition is substrate dependent. We have previously shown that P-gp genetic variants have different sensitivities to cyclosporine inhibition and that P-gp inhibition is substrate-dependent [34]. A second difference in the assays was the use of fluorescence versus radioactivity. Several of the dyes that were tested (D&C Red No. 28, D&C Red No. 27 and D&C Red No. 3) interfered with fluorescence measurements for calcein accumulation as well as permeability measurements using lucifer yellow. Differences in sensitivity of transport measurement between the two substrates are also possible, although the common use of both calcein-AM and digoxin for P-gp assays makes this less likely [57]. A final difference in the assays is the cell types, a human kidney epithelial

cell for the calcein-AM assay and a canine kidney epithelial cell that is polarized on a semipermeable membrane for the digoxin assay. Differences in the permeability of the tested excipients between the two cell lines cannot be ruled out.

Despite these limitations, consistent results between the current findings and published studies support the validity of this screen. A recent evaluation of the effect of common food additives on P-gp function demonstrated minimal effects, including many that showed no inhibition in the current calcein-AM and digoxin screens (acesulfame K, aspartame, neohesperidin DC, neotame, sucralose, DL-malic acid, fumaric acid, methylparaben and ethylparaben) [58]. Additional excipients previously tested against P-gp with similar negative results as the current study include lactose monohydrate, sorbitol, sucrose palmitate, sucrose monolaurate and sodium lauryl sulfate [18, 21, 40, 41, 59–61]. However, excipients such as polyethylene glycols, polysorbates, Cremophor EL and pluronics have been shown to improve intestinal absorption of P-gp substrates using *in situ* and animal models by inhibiting P-gp activity [18–27, 61]. The current data expands the list of molecular excipients that have been characterized with respect to P-gp interactions, allowing for more informed decisions with regard to excipient selection for drug formulation.

Conclusion

In conclusion, a large number of oral molecular excipients were shown to not interact with human P-gp, a critical membrane transporter in the human intestine. These data suggest that diverse molecular excipients can be used in orally administered drug products with limited risk of influencing the bioavailability of P-gp substrates. While β -CD and light green SF yellowish modestly inhibited human P-gp *in vitro* and, thus, are not likely to have significant effects in humans, careful evaluation for their inclusion in new formulations may be warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank Drs. Per Artutsson and Maria Kalgren for the MDCK-hMDR1-cMDR1-knock out stable cell lines. We also thank Drs. Xiaomin Liang (Gilead Sciences) and Eugene Chen (Genentech) for advice on the digoxin flux assays. Drs. Chenling Xiong, Katherina Chua, Josefina Priotti and Nura El-Haj provided insightful discussions of the data.

Funding Statement

This research was made possible by Grant U01FD004979/U01FD005978 from the US Food and Drug Administration (FDA), which supports the University of California, San Francisco - Stanford Center of Excellence in Regulatory Sciences and Innovation (UCSF-Stanford CERSI). Funding for the research described in the article was provided by the Office of Generic Drugs through the UCSF-Stanford CERSI. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS or FDA. Ruchika Bajaj was partially supported by American Heart Association postdoctoral fellowship Award No. 19POST34370101.

References

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. *Nat Rev Drug Discov.* 2010;9:215–36. [PubMed: 20190787]
2. Lund M, Petersen TS, Dalhoff KP. Clinical implications of P-glycoprotein modulation in drug-drug interactions. *Drugs.* 2017;77:859–83. [PubMed: 28382570]
3. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. *Drug Metab Rev.* 2002;34:47–54. [PubMed: 11996011]
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. *Clin Pharmacokinet.* 2003;42:59–98. [PubMed: 12489979]
5. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci U S A.* 1987;84:7735–8. [PubMed: 2444983]
6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer.* 2002;2:48–58. [PubMed: 11902585]
7. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Deliv Rev.* 2003;55:3–29. [PubMed: 12535572]
8. Kaur G, Arora M, Ravi Kumar MNV. Oral drug delivery technologies-A decade of developments. *J Pharmacol Exp Ther.* 2019;370:529–43. [PubMed: 31010845]
9. Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, et al. Preference for pharmaceutical formulation and treatment process attributes. *Patient Prefer Adherence.* 2016;10:1385–99. [PubMed: 27528802]
10. Hamman J, Steenekamp J. Excipients with specialized functions for effective drug delivery. *Expert Opin Drug Deliv.* 2012;9:219–30. [PubMed: 22196483]
11. Panakanti R, Narang AS. Impact of excipient interactions on drug bioavailability from solid dosage forms. *Pharm Res.* 2012;29:2639–59. [PubMed: 22610283]
12. Darji MA, Lalge RM, Marathe SP, Mulay TD, Fatima T, Alshammari A, et al. Excipient stability in oral solid dosage forms: A review. *AAPS PharmSciTech.* 2018;19:12–26. [PubMed: 28895106]
13. Palcso B, Zelko R. Different types, applications and limits of enabling excipients of pharmaceutical dosage forms. *Drug Discov Today Technol.* 2018;27:21–39. [PubMed: 30103860]
14. Dave VS, Saoji SD, Raut NA, Haware RV. Excipient variability and its impact on dosage form functionality. *J Pharm Sci.* 2015;104:906–15. [PubMed: 25561249]
15. Garcia-Arieta A Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence. *Eur J Pharm Sci.* 2014;65:89–97.
16. Zarnpi P, Flanagan T, Meehan E, Mann J, Fotaki N. Biopharmaceutical aspects and implications of excipient variability in drug product performance. *Eur J Pharm Biopharm.* 2017;111:1–15. [PubMed: 27845182]
17. Pottel J, Armstrong D, Zou L, Fekete A, Huang XP, Torosyan H, et al. The activities of drug inactive ingredients on biological targets. *Science.* 2020;369:403–13. [PubMed: 32703874]
18. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. *Int J Pharm.* 2004;278:119–31. [PubMed: 15158955]
19. Cornaire G, Woodley JF, Saivin S, Legendre JY, Decourt S, Cloarec A, et al. Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro. *Arzneimittel-Forschung-Drug Research.* 2000;50:576–9. [PubMed: 10918954]
20. Guan Y, Huang J, Zuo L, Xu J, Si L, Qiu J, et al. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. *Arch Pharm Res.* 2011;34:1719–28. [PubMed: 22076772]
21. Gurjar R, Chan CYS, Curley P, Sharp J, Chiong J, Rannard S, et al. Inhibitory effects of commonly used excipients on P-glycoprotein in vitro. *Molecular Pharmaceutics.* 2018;15:4835–42. [PubMed: 30350641]
22. Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. *J Pharm Sci.* 2002;91:1980–90. [PubMed: 12210045]

23. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. *Journal of Pharmaceutical Sciences*. 2002;91:1991–2002. [PubMed: 12210046]
24. Katneni K, Charman SA, Porter CJ. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. *J Pharm Sci*. 2007;96:280–93. [PubMed: 17051595]
25. Lo YL, Huang JD. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. *Biochemical Pharmacology*. 2000;59:665–72. [PubMed: 10677583]
26. Ma L, Wei Y, Zhou Y, Ma X, Wu X. Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. *Arch Pharm Res*. 2011;34:1939–43. [PubMed: 22139693]
27. Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. *Arch Pharm Res*. 2003;26:768–72. [PubMed: 14560928]
28. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. *Eur J Pharm Sci*. 2005;25:445–53.
29. Ashiru DA, Patel R, Basit AW. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. *Pharm Res*. 2008;25:2327–33. [PubMed: 18600434]
30. Li M, Si L, Pan H, Rabba AK, Yan F, Qiu J, et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. *Int J Pharm*. 2011;403:37–45. [PubMed: 20969937]
31. Shen Y, Lu Y, Jv M, Hu J, Li Q, Tu J. Enhancing effect of Labrasol on the intestinal absorption of ganciclovir in rats. *Drug Dev Ind Pharm*. 2011;37:1415–21. [PubMed: 21623688]
32. Administration USFD. Inactive Ingredient Search for Approved Drug Products. U.S. Food & Drug Administration; 2020 [updated 01/21/2021]. Available from: <https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm>.
33. Zou L, Spanogiannopoulos P, Pieper LM, Chien HC, Cai W, Khuri N, et al. Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. *Proc Natl Acad Sci U S A*. 2020;117:16009–18. [PubMed: 32571913]
34. Gow JM, Hodges LM, Chinn LW, Kroetz DL. Substrate-dependent effects of human ABCB1 coding polymorphisms. *J Pharmacol Exp Ther*. 2008;325:435–42. [PubMed: 18287207]
35. Karlgren M, Simoff I, Backlund M, Wegler C, Keiser M, Handin N, et al. A CRISPR-Cas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (cABCB1): An improved tool for drug efflux studies. *J Pharm Sci*. 2017;106:2909–13. [PubMed: 28450237]
36. Simoff I, Karlgren M, Backlund M, Lindstrom AC, Gaugaz FZ, Matsson P, et al. Complete knockout of endogenous Mdr1 (Abcb1) in MDCK cells by CRISPR-Cas9. *J Pharm Sci*. 2016;105:1017–21. [PubMed: 26869442]
37. Levy ES, Samy KE, Lamson NG, Whitehead KA, Kroetz DL, Desai TA. Reversible inhibition of efflux transporters by hydrogel microdevices. *Eur J Pharm Biopharm*. 2019;145:76–84. [PubMed: 31639417]
38. Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. *Nat Protoc*. 2007;2:2111–9. [PubMed: 17853866]
39. Gerber W, Hamman JH, Steyn JD. Excipient-drug pharmacokinetic interactions: Effect of disintegrants on efflux across excised pig intestinal tissues. *J Food Drug Anal*. 2018;26:S115–S24. [PubMed: 29703379]
40. Takizawa Y, Goto N, Furuya T, Hayashi M. Influence of pharmaceutical excipients on the membrane transport of a P-glycoprotein substrate in the rat small intestine. *Eur J Drug Metab Pharmacokinet*. 2020;45:645–52. [PubMed: 32583315]
41. Takizawa Y, Kishimoto H, Nakagawa M, Sakamoto N, Tobe Y, Furuya T, et al. Effects of pharmaceutical excipients on membrane permeability in rat small intestine. *Int J Pharm*. 2013;453:363–70. [PubMed: 23742974]

42. Conceicao J, Adeoye O, Cabral-Marques HM, Lobo JMS. Cyclodextrins as excipients in tablet formulations. *Drug Discov Today*. 2018;23:1274–84. [PubMed: 29689302]
43. Zhang Y, Cui YL, Gao LN, Jiang HL. Effects of beta-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. *Int J Biol Macromol*. 2013;59:363–71. [PubMed: 23664937]
44. Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. *J Pharmacol Exp Ther*. 2001;297:547–55. [PubMed: 11303042]
45. Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. *Pharm Res*. 2004;21:625–34. [PubMed: 15139519]
46. Cai C, Zhu H, Chen J. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. *Biochem Biophys Res Commun*. 2004;320:868–74. [PubMed: 15240128]
47. Kamau SW, Kramer SD, Gunthert M, Wunderli-Allenspach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. *In Vitro Cell Dev Biol Anim*. 2005;41:207–16. [PubMed: 16223335]
48. Pathak SM, Musmade P, Denge S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with methyl-beta-cyclodextrin-Preparation and in vitro and in vivo evaluation. *Eur J Pharm Sci*. 2010;41:440–51. [PubMed: 20656025]
49. Yunomae K, Arima H, Hirayama F, Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. *FEBS Lett*. 2003;536:225–31. [PubMed: 12586368]
50. Durk MR, Jones NS, Liu J, Nagapudi K, Mao C, Plise EG, et al. Understanding the effect of hydroxypropyl-beta-cyclodextrin on fenebrutinib absorption in an itraconazole-fenebrutinib drug-drug interaction study. *Clin Pharmacol Ther*. 2020;108:1224–32. [PubMed: 32535897]
51. Zou L, Pottel J, Khuri N, Ngo HX, Ni Z, Tsakalozou E, et al. Interactions of oral molecular excipients with breast cancer resistance protein, BCRP. *Mol Pharm*. 2020;17:748–56. [PubMed: 31990564]
52. Administration USFD. *In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry*. U.S. Food & Drug Administration; 2020 [updated 05/07/2020]. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions>.
53. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. *Anticancer Drugs*. 1996;7:568–78. [PubMed: 8862725]
54. Caetano-Pinto P, Janssen MJ, Gijzen L, Verscheijden L, Wilmer MJ, Masereeuw R. Fluorescence-based transport assays revisited in a human renal proximal tubule cell line. *Mol Pharm*. 2016;13:933–44. [PubMed: 26871298]
55. Olson DP, Taylor BJ, Ivy SP. Detection of MRP functional activity: Calcein AM but not BCECF AM as a Multidrug Resistance-related Protein (MRP1) substrate. *Cytometry*. 2001;46:105–13. [PubMed: 11309820]
56. Reznicek J, Ceckova M, Ptackova Z, Martinec O, Tupova L, Cerveny L, et al. MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption. *Antimicrob Agents Chemother*. 2017;61.
57. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. *J Med Chem*. 2003;46:1716–25. [PubMed: 12699389]
58. Sjostedt N, Deng F, Rauvala O, Tepponen T, Kidron H. Interaction of food additives with intestinal efflux transporters. *Mol Pharm*. 2017;14:3824–33. [PubMed: 28921988]
59. Kiss L, Hellinger E, Pilbat AM, Kittel A, Torok Z, Furedi A, et al. Sucrose esters increase drug penetration, but do not inhibit P-glycoprotein in caco-2 intestinal epithelial cells. *J Pharm Sci*. 2014;103:3107–19. [PubMed: 25042090]

60. Lo YL. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. *J Control Release*. 2003;90:37–48. [PubMed: 12767705]
61. Ruiz-Picazo A, Gonzalez-Alvarez M, Gonzalez-Alvarez I, Bermejo M. Effect of common excipients on intestinal drug absorption in Wistar rats. *Mol Pharm*. 2020;17:2310–8. [PubMed: 32469522]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1.
Design of screening for interaction of oral molecular excipients with P-gp.




Figure 2. Identification of oral molecular excipients as P-gp inhibitors using a calcein-AM assay. [A] Difference in calcein fluorescence of HEK-empty vector (EV) and HEK-MDR1 (P-gp) cells after incubation with 5 μ M calcein-AM in the absence and presence of the known P-gp inhibitor verapamil (62.5 μ M). The mean of four replicates for the HEK-MDR1 cells was normalized to 1. Values are shown for each replicate and the lines represent the mean value. [B] The data in panel A were transformed into normalized calcein accumulation ratios by taking the ratio of fluorescence in the presence and absence of verapamil in the HEK-MDR1 cells to the ratio of fluorescence in the presence and absence of verapamil in the HEK-EV cells. Values are shown for each replicate and the line represents the mean value. [C] Normalized calcein accumulation ratios for 123 oral excipients are shown in decreasing order. The dashed line at 1.4 represents the cut-off used to assign potential inhibitors. [D] A scatter plot of the P-gp ratio with the EV ratio for the 123 molecular excipients that were screened is shown. The dashed line at 1.4 represents the cut off used to assign inhibition of P-gp. Excipients that inhibit P-gp at least 40% in the HEK-MDR1 cells and have no effect in the HEK-EV cells are labeled.




Figure 3.

Identification of oral molecular excipients as P-gp inhibitors using a digoxin flux assay.

[A] The rate of basal to apical digoxin flux in canine MDR1 knockout (cMDR1-KO) and canine MDR1 knockout overexpressing human MDR1 (hMDR1) MDCK cells is shown in the absence and presence of the known P-gp inhibitor cyclosporine (10 μM). Digoxin flux rates are normalized to the average in the absence of inhibitor in the cMDR1-KO cells. Values are shown for each replicate and the lines represent the mean value. [B] Fold change in digoxin flux rate for 123 oral molecular excipients in decreasing order. The dashed line at 0.6 represents the cut-off used to identify putative inhibitors. [C] Scatter plot of fold change in digoxin flux rate with respect to mean lucifer yellow permeability for the 123 oral excipients that were screened. Excipients that inhibit digoxin flux at least 40% and with lucifer yellow permeability <3% are labeled. Disruptions in both axes are used for better visualization of the data. [D and E] Representative excipient dose-response curves for the two putative P-gp inhibitors identified in the screening. Individual replicates from a single experiment are plotted. The curve was fit using the log(inhibitor) vs. response – variable slope (four parameters) relationship in GraphPad Prism 9. IC₅₀ estimates were 168 μM (95% CI = 118–251 μM) for β-cyclodextrin and 204 μM (95% CI = 5.9–1745 μM) for light green SF yellowish.

[D and E] Representative excipient dose-response curves for the two putative P-gp inhibitors identified in the screening. Individual replicates from a single experiment are plotted. The curve was fit using the log(inhibitor) vs. response – variable slope (four parameters) relationship in GraphPad Prism 9. IC₅₀ estimates were 168 μM (95% CI = 118–251 μM) for β-cyclodextrin and 204 μM (95% CI = 5.9–1745 μM) for light green SF yellowish.

Table I.

Summary of results from calcein-AM and digoxin screening assays

Excipient	Functional Category	Calcein-AM Assay				Digoxin Assay		
		Normalized Accumulation Ratio ²	EV Ratio ³	MDRI Ratio ⁴	Classification ⁵	Fold Change in Flux ⁶	Lucifer Yellow Permeability (%) ⁷	Classification ⁸
D&C Red No. 28	Dye	2.60	0.10	0.26	False positive	0.45	186	Fluorescent
Benzalkonium chloride	Antimicrobial	2.34	0.07	0.17	False positive	3.87	7.79	Permeabilizer
D&C Red No. 27	Dye	2.30	0.14	0.32	False positive	0.75	211	Fluorescent
Docusate sodium	Surfactant	2.16	0.22	0.49	False positive	2.47	7.6	Permeabilizer
D&C Red No. 3	Dye	1.88	0.41	0.77	False positive	1.02	65.6	Fluorescent
D&C Red No. 33	Dye	1.78	0.02	0.04	False positive	1.18	0.11	Inert
D&C Red No. 6	Dye	1.58	0.92	1.47	Inhibitor	1.20	0.14	Inert
D&C Brown No. 1	Dye	1.58	0.94	1.48	Inhibitor	0.68	0.15	Inert
NaHCO ₃	Buffering agent	1.57	0.88	1.38	Inert	1.55	0.12	Non-specific
D&C Orange No. 4	Dye	1.53	0.06	0.10	False positive	0.96	0.15	Inert
Naphthol blue black	Dye	1.38	1.15	1.60	Inert	1.08	0.01	Inert
FD&C Red No. 4	Dye	1.38	0.83	1.15	Inert	1.28	0.12	Inert
Butylparaben	Antimicrobial	1.37	1.15	1.58	Inert	1.08	0.38	Inert
Epilactose	Other	1.35	0.79	1.07	Inert	0.80	0.08	Inert
Acid blue 9	Dye	1.34	1.56	2.09	Inert	0.67	0.22	Inert
Sodium 1,2-ethanedithiolate	Salt forming	1.29	0.87	1.13	Inert	1.11	0.11	Inert
Light green CF yellowish	Dye	1.28	1.44	1.85	Inert	0.55	0.31	Inhibitor
Dextrose	Flavoring agent	1.27	0.89	1.15	Inert	0.99	0.11	Inert
FD&C Yellow No. 5	Dye	1.23	0.84	1.04	Inert	1.03	0.57	Inert
Rhodamine B	Dye	1.21	0.97	1.17	Inert	0.38	11.3	Permeabilizer
Fumaric acid	Flavoring agent	1.18	0.90	1.06	Inert	0.69	0.11	Inert
Sodium salicylate	Other	1.17	0.87	1.02	Inert	1.15	1.25	Inert
Dibutyl sebacate	Plasticizer	1.16	1.05	1.22	Inert	0.96	0.11	Inert
Ethanol	Antimicrobial	1.16	0.91	1.06	Inert	0.86	0.06	Inert
Indigo carmine	Dye	1.15	0.85	0.98	Inert	1.06	0.08	Inert

Excipient	Functional Category ¹	Calcein-AM Assay				Digoxin Assay		
		Normalized Accumulation Ratio ²	EV Ratio ³	MDRI Ratio ⁴	Classification ⁵	Fold Change in Flux ⁶	Lucifer Yellow Permeability (%) ⁷	Classification ⁸
Erythritol	Flavoring agent	1.15	0.90	1.03	Inert	0.93	0.05	Inert
Ethyl vanillin	Flavoring agent	1.14	1.08	1.23	Inert	1.07	0.19	Inert
Ethyl maltol	Flavoring agent	1.12	0.90	1.00	Inert	0.96	0.09	Inert
Tributyl-2-acetyl citrate	Plasticizer	1.08	0.91	0.98	Inert	1.10	0.13	Inert
Sucrose	Coating agent	1.07	0.82	0.88	Inert	1.03	0.20	Inert
Sodium bitartrate	Flavoring agent	1.06	1.06	1.13	Inert	1.28	0.29	Inert
Oil orange SS	Dye	1.05	0.87	0.92	Inert	1.89	0.38	Non-specific
L-ascorbic acid	Antioxidant	1.05	0.81	0.85	Inert	1.08	0.29	Inert
Butyl alcohol	Solubilizer	1.04	1.09	1.15	Inert	1.19	0.13	Inert
FD&C Red No. 40	Dye	1.04	1.09	1.15	Inert	1.25	0.03	Inert
Ammonium glycyrrhizate	Flavoring agent	1.04	1.11	1.2	Inert	1.54	0.11	Non-specific
Na ₃ PO ₄	Buffering agent	1.04	1.35	1.40	Inert	1.48	0.09	Non-specific
Succinic acid	Flavoring agent	1.03	0.95	0.98	Inert	0.86	0.13	Inert
Ponceau 3R	Dye	1.03	0.99	1.02	Inert	0.97	0.05	Inert
2-Ethoxyethanol	Solvent	1.02	0.93	0.95	Inert	1.37	0.08	Inert
Pigment yellow 62	Dye	1.02	1.18	1.21	Inert	0.99	0.05	Inert
Carmine	Dye	1.02	1.25	1.28	Inert	1.26	0.16	Inert
Ponceau xylidine	Dye	1.01	1.06	1.08	Inert	1.05	0.09	Inert
Propyl gallate	Antimicrobial	1.00	1.22	1.23	Inert	1.54	0.31	Non-specific
Cetyl alcohol	Coating agent	1.00	1.18	1.18	Inert	0.82	0.09	Inert
Sodium benzoate	Antimicrobial	0.99	0.84	0.84	Inert	0.99	0.18	Inert
Triethyl citrate	Plasticizer	0.99	0.86	0.86	Inert	1.04	0.33	Inert
EDTA	Chelator	0.99	1.01	1.01	Inert	0.93	0.09	Inert
L-arginine	Nutrient suppl.	0.99	1.14	1.13	Inert	1.33	0.07	Inert
D-tagatose	Flavoring agent	0.98	1.03	1.01	Inert	1.08	0.06	Inert
Acesulfame potassium	Flavoring agent	0.98	0.86	0.85	Inert	1.04	2.08	Inert
Neotame	Flavoring agent	0.98	1.08	1.07	Inert	0.97	0.11	Inert

Excipient	Functional Category ¹	Calcein-AM Assay				Digoxin Assay		
		Normalized Accumulation Ratio ²	EV Ratio ³	MDRI Ratio ⁴	Classification ⁵	Fold Change in Flux ⁶	Lucifer Yellow Permeability (%) ⁷	Classification ⁸
Vanillin	Flavoring agent	0.98	0.97	0.95	Inert	1.33	0.04	Inert
Propylparaben	Antimicrobial	0.97	1.19	1.15	Inert	1.43	0.20	Inert
Xylitol	Flavoring agent	0.97	1.10	1.07	Inert	1.37	0.06	Inert
Ext D&C yellow No. 7	Dye	0.97	1.20	1.16	Inert	1.23	0.14	Inert
Potassium sorbate	Antimicrobial	0.96	1.19	1.15	Inert	1.45	0.10	Non-specific
Sorbitol	Diluent	0.96	0.87	0.85	Inert	0.97	0.13	Inert
Glycerin	Antimicrobial	0.96	0.85	0.82	Inert	0.88	0.28	Inert
Sodium gluconate	Nutrient suppl.	0.96	1.10	1.06	Inert	1.10	0.18	Inert
Propylene glycol	Antimicrobial	0.96	0.85	0.81	Inert	1.32	0.27	Inert
Sodium acetate	Antimicrobial	0.95	1.20	1.15	Inert	1.16	0.11	Inert
Butylated hydroxytoluene	Antioxidant	0.95	0.99	0.95	Inert	1.45	2.57	Non-specific
Calcium pyrophosphate	Nutrient suppl.	0.95	1.07	1.02	Inert	1.05	0.05	Inert
Transanethol	Flavoring agent	0.94	1.20	1.14	Inert	1.28	0.31	Inert
Maltilol	Flavoring agent	0.94	1.05	0.98	Inert	1.01	0.09	Inert
Lactose monohydrate	Diluent	0.93	0.99	0.93	Inert	1.25	0.09	Inert
Isopropanol	Antimicrobial	0.93	1.04	0.97	Inert	1.01	0.10	Inert
Sodium lauryl sulfate	Surfactant	0.93	0.92	0.86	Inert	2.23	7.98	Permeabilizer
Glycine	Buffering agent	0.92	1.06	0.97	Inert	1.36	0.11	Inert
L-Malic acid	Flavoring agent	0.92	1.17	1.08	Inert	1.21	0.12	Inert
Acetophenone	Solubilizer	0.92	1.14	1.05	Inert	1.20	0.04	Inert
Mannose	Flavoring agent	0.91	1.14	1.04	Inert	1.00	0.06	Inert
Methanolamine	Buffering agent	0.91	1.13	1.03	Inert	1.11	0.11	Inert
Sodium thiosulfate	Antioxidant	0.91	0.97	0.88	Inert	0.99	0.11	Inert
Na ₂ HPO ₄	Buffering agent	0.91	1.04	0.94	Inert	1.34	0.06	Inert
Glyceryl caprylate	Surfactant	0.90	1.08	0.97	Inert	1.05	0.13	Inert
Methylparaben sodium	Antimicrobial	0.90	1.10	0.99	Inert	1.59	0.07	Non-specific
Sodium citrate	Buffering agent	0.89	1.11	1.00	Inert	1.13	0.18	Inert

Excipient	Functional Category ¹	Calcein-AM Assay				Digoxin Assay		
		Normalized Accumulation Ratio ²	EV Ratio ³	MDRI Ratio ⁴	Classification ⁵	Fold Change in Flux ⁶	Lucifer Yellow Permeability (%) ⁷	Classification ⁸
Mannitol	Diluent	0.89	1.22	1.08	Inert	1.24	0.13	Inert
Methanol	Solubilizer	0.89	1.02	0.92	Inert	1.05	0.10	Inert
L-Histidine	Nutrient suppl.	0.89	1.09	0.98	Inert	1.18	0.22	Inert
Piperazine	Flavoring agent	0.88	1.05	0.94	Inert	1.58	0.07	Non-specific
Tromethamine	Buffering agent	0.87	1.28	1.12	Inert	1.29	0.07	Inert
Cinnamaldehyde	Flavoring agent	0.87	1.10	0.96	Inert	3.14	103	Fluorescent
DL- α -tocopherol acetate	Antioxidant	0.87	1.19	1.05	Inert	1.50	0.09	Non-specific
Meglumine	Buffering agent	0.87	1.24	1.07	Inert	1.02	0.11	Inert
Maleic acid	Buffering agent	0.87	1.06	0.92	Inert	1.13	0.09	Inert
Ethylparaben	Antimicrobial	0.87	1.27	1.11	Inert	1.10	0.14	Inert
Galactose	Flavoring agent	0.86	1.09	0.94	Inert	1.34	0.06	Inert
Malic acid	Flavoring agent	0.86	1.12	0.97	Inert	1.14	0.08	Inert
Tartaric acid	Flavoring agent	0.86	1.14	0.98	Inert	1.47	0.08	Non-specific
Glutamic acid	Nutrient suppl.	0.86	1.18	1.02	Inert	0.72	0.12	Inert
Lactitol	Diluent	0.86	1.03	0.89	Inert	1.17	0.09	Inert
Isomalt	Coating agent	0.86	1.06	0.91	Inert	1.52	0.08	Non-specific
Amamath	Dye	0.86	1.22	1.05	Inert	1.12	0.02	Inert
NaH ₂ PO ₄	Buffering agent	0.85	1.04	0.89	Inert	1.31	0.06	Inert
Maltose	Flavoring agent	0.85	1.11	0.95	Inert	1.61	0.10	Non-specific
Urea	Surfactant	0.85	1.28	1.08	Inert	1.21	0.07	Inert
Neohesperidin dihydrochalcone	Flavoring agent	0.84	1.13	0.96	Inert	1.61	0.18	Non-specific
Sodium sulfite	Antimicrobial	0.84	1.04	0.87	Inert	0.95	0.09	Inert
Myristyl alcohol	Emollient	0.83	1.24	1.03	Inert	0.90	0.08	Inert
FD&C yellow No. 6	Dye	0.82	1.25	1.02	Inert	1.03	0.19	Inert
Fructose	Flavoring agent	0.82	1.06	0.87	Inert	1.36	0.14	Inert
Methacrylic acid	Other	0.81	1.38	1.13	Inert	1.10	0.08	Inert
Acetone	Solubilizer	0.81	1.14	0.93	Inert	1.08	0.06	Inert

Excipient	Functional Category ¹	Calcein-AM Assay				Digoxin Assay		
		Normalized Accumulation Ratio ²	EV Ratio ³	MDR1 Ratio ⁴	Classification ⁵	Fold Change in Flux ⁶	Lucifer Yellow Permeability (%) ⁷	Classification ⁸
DL-Aspartic acid	Nutrient suppl.	0.81	1.30	1.06	Inert	1.14	0.07	Inert
Sodium 4-aminobenzoate	Other	0.79	1.12	0.89	Inert	1.03	0.13	Inert
Sucrose palmitate	Surfactant	0.79	1.30	1.04	Inert	1.48	2.60	Non-specific
Aspartame	Flavoring agent	0.79	1.29	1.03	Inert	1.18	0.10	Inert
Chloromethane	Other	0.79	1.22	0.97	Inert	1.38	0.04	Inert
β-Cyclodextrin	Solubilizer	0.79	1.18	0.94	Inert	0.25	0.14	Inhibitor
Maltol	Flavoring agent	0.78	1.04	0.82	Inert	0.96	0.09	Inert
MgSO ₄	Nutrient suppl.	0.77	1.22	0.94	Inert	0.84	0.04	Inert
Sucralose	Flavoring agent	0.75	0.98	0.74	Inert	1.11	0.16	Inert
Sodium carbonate	Buffering agent	0.72	1.24	0.90	Inert	1.39	0.19	Inert
Ethyl acetate	Flavoring agent	0.71	1.29	0.91	Inert	1.07	0.06	Inert
Leucine	Flavoring agent	0.69	1.07	0.75	Inert	1.40	0.06	Inert
DL-Lactic acid	Flavoring agent	0.67	1.31	0.88	Inert	1.15	0.07	Inert
Cysteine hydrochloride	Nutrient suppl.	0.66	1.33	0.87	Inert	1.05	0.06	Inert
Sucrose monolaurate	Surfactant	0.53	1.28	0.68	Non-specific	1.54	2.24	Non-specific
Yellow AB	Dye	0.44	0.38	0.17	Non-specific	1.81	0.14	Non-specific
Cetylpyridinium chloride	Antimicrobial	0.18	0.34	0.06	Non-specific	3.35	6.22	Permeabilizer

¹The most common use is noted for most excipients. For those marked 'Other' no clear indication was available.

²Normalized accumulation ratio = $\frac{P-gp+I}{EV+I} \frac{P-gp-I}{EV-I}$ where (P-gp + I) and (P-gp - I) represent the fluorescence of accumulated calcein in HEK-MDR1 cells in the presence and absence of the test compound, respectively and (EV + I) and (EV - I) represent the fluorescence of accumulated calcein in the HEK-EV cells in the presence and absence of the test compound, respectively.

³EV ratio = $\frac{EV+I}{EV-I}$ where (EV + I) and (EV - I) represent the fluorescence of accumulated calcein in the HEK-EV cells in the presence and absence of the test compound, respectively.

⁴MDR1 ratio = $\frac{P-gp+I}{P-gp-I}$ where (P-gp + I) and (P-gp - I) represent the fluorescence of accumulated calcein in the HEK-MDR1 cells in the presence and absence of the test compound, respectively.

⁵Excipients were classified as inhibitors if the normalized accumulation ratio was 1.40 and the MDR1 ratio was 1.40. Excipients with a normalized accumulation ratio 1.40 with decreased ratios in both the EV and MDR1 cells were classified as false positives. Excipients with a normalized accumulation ratio 0.60 were classified as non-specific activators. All other excipients were considered inert.

⁶Fold change in flux is the ratio of digoxin flux in the basal to apical direction in the presence and absence of the indicated excipient.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

⁷ Lucifer yellow permeability is the percentage of lucifer yellow that moved from the apical to the basal chamber during the 2 hr flux assay.

⁸ Excipients were classified as inhibitors if the fold change in digoxin flux was 0.60 and lucifer yellow permeability was <3%. Excipients that interfered with the lucifer yellow measurement (permeability >50%) were classified as fluorescent and those that increased lucifer yellow permeability >3% and 50% were classified as permeabilizers. Excipients that increased digoxin flux 40% were classified as non-specific activators. All other excipients were considered inert.